{"disease":{"id":"alk-gene-mutation","name":"alk gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04322890","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT05534854","title":"Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05110950","title":"Endobronchial Ultrasound Needle Aspiration With and Without Suction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":306,"lead_sponsor_name":"Università Politecnica delle Marche","has_results":false},{"nct_id":"NCT04042558","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT06234579","title":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","phase":"","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03042221","title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT05266846","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT05724004","title":"Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT02259114","title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT05713006","title":"Alectinib Pharmacokinetic in Patients With NSCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT03049618","title":"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04708639","title":"Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT04013542","title":"Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03944265","title":"Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT04849273","title":"A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02846792","title":"Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03868423","title":"Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Sameek Roychowdhury","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}